In addition to ibrutinib, people with M-CLL, devoid of TP53 aberrations and healthy enough to tolerate FCR therapy, should still be great candidates with the latter, Using the advantage currently being this procedure might be finished in six months even though ibrutinib must be taken indefinitely. This option will be specially important for non-com